Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08NYL
|
|||
| Former ID |
DCL001066
|
|||
| Drug Name |
AGN211745
|
|||
| Drug Type |
siRNA drug
|
|||
| Indication | Choroidal neovascularization [ICD-11: 9B76; ICD-10: H35; ICD-9: 362.5] | Discontinued in Phase 2 | [1] | |
| Therapeutic Class |
siRNA
|
|||
| Company |
Allergan
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | VEGFR2 messenger RNA (VEGFR2 mRNA) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019725) | |||
| REF 2 | Teaming up to tackle RNAi delivery challenge. Nat Rev Drug Discov. 2009 Jul;8(7):525-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.